SectorBiological Technology
Established Date--
Listing Date07/04/2021
ExchangeNASDAQ Stock Exchange
Full-time Employees13
Fiscal Year Ends31/12
Security TypeCommon stock
Office address12 Abba Hillel Road, Ramat-Gan, Israel 5250606
Business
IntroductionSilexion Therapeutics Corp is a Cayman Islands exempted company. The Company is a clinical-stage, oncology-focused biotechnology company developing proprietary therapies for KRAS mutation-driven cancers. Its lead drug candidate, SIL204, is a second-generation small interfering RNA designed to inhibit production of the mutant KRAS protein, initially targeting locally advanced pancreatic cancer.
